This trial is active, not recruiting.

Condition pulmonary arterial hypertension
Treatments macitentan 10 mg, placebo
Phase phase 3
Sponsor Actelion
Start date May 2013
End date December 2016
Trial size 220 participants
Trial identifier NCT01743001, AC-055-305


Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Subjects receive macitentan 10 mg oral tablet once daily
macitentan 10 mg ACT-064992
Macitentan 10 mg oral tablet once daily
(Placebo Comparator)
Subjects receive macitentan-matching placebo oral tablet once daily
Macitentan-matching placebo oral tablet once daily

Primary Outcomes

Change from baseline to Week 16 in exercise capacity, as measured by 6MWD
time frame: From baseline to Week 16

Secondary Outcomes

Change from baseline to Week 16 in WHO functional class
time frame: From baseline to Week 16
Change from baseline to Week 16 in dyspnea (assessed by the Borg dyspnea index)
time frame: From baseline to Week 16
Change from baseline to Week 16 in quality of life (assessed by the SF-36 questionnaire)
time frame: From baseline to Week 16

Eligibility Criteria

Male or female participants at least 12 years old.

Inclusion Criteria: - Subjects: - not participating in the hemodynamic sub-study: males or females ≥ 12 years of age. - participating in the hemodynamic sub-study: males or females ≥ 18 years of age. - Subjects (including those with Down Syndrome [DS]) with confirmed Eisenmenger Syndrome [ES] (European Society of Cardiology [ESC] and the European Respiratory Society [ERS] guidelines): 1. Established by echocardiography as: - Large congenital shunting defect at atrial, ventricular or arterial level* - and right to left shunt or bi-directional shunt with prevalent right to left direction. 2. Resting peripheral oxygen saturation (SpO2) ≤ 90% and > 70% (pulse oximetry, room air). The lower limit is 65% if a subject is living at an altitude greater than 2500 m above sea level. *Subjects with any of the following open defects are eligible for the study either as an isolated defect or in combination: - atrial septal defect (ASD) - ventricular septal defect (VSD) - partial or complete atrioventricular septal defect (AVSD) - patent ductus arteriosus (PDA) - aortopulmonary window (AP window) - total or partial anomalous pulmonary venous return (TAPVR, PAPVR) The defects may be either unoperated or previously palliated surgically (provided significant residual defect remains). The Steering Committee will review the echocardiography data of all subjects (main study and sub study) to confirm eligibility prior to Randomization. - Subjects with the following findings at cardiac catheterization: - Mean resting pulmonary arterial pressure (mPAP) > 25 mmHg - Pulmonary capillary wedge pressure (PCWP) or mean left atrial pressure (LAP) or left ventricular end diastolic pressure (LVED) ≤ 15 mmHg - Pulmonary vascular resistance (PVR) ≥ 800 dyn∙s/cm5 or ≥ 10 Wood units - Subjects with WHO functional class ≥ II. - Subjects able to reliably perform the the 6-minute walk test (6MWT) with a minimum distance of 50 m and a maximum distance of 450 m. Exclusion Criteria: - Main study and hemodynamic sub-study: Any of the following conditions previously known or identified via cardiac catheterization or echocardiography: - Pulmonary arterial or venous stenosis > 25% size of native pulmonary artery (PA) or pulmonary vein - Severe tricuspid regurgitation in the setting of left to right shunt at the ventricular or atrial level - Greater than mild tricuspid stenosis - Intracavitary RV outflow obstruction - Greater than mild mitral stenosis - Intracavitary LV outflow obstruction - Subvalvular or supravalvular aortic stenosis - Aortic coarctation - Greater than moderate mitral regurgitation - Recognized extracardiac systemic venous collaterals to the pulmonary venous circulation - Recognized hepatic wedge pressure-inferior vena cava pressure gradient >12 mm Hg - PCWP "v" waves >20 mmHg - Tetralogy of Fallot - Truncus arteriosus - Interrupted aortic arch - Transposition of great arteries - Single ventricle defects: absent AV connection (mitral or tricuspid atresia), double inlet AV connections left or right ventricle, functional univentricular heart (unbalanced AVSD, hypoplastic RV, double outlet RV), hypoplastic left heart syndrome - Ebstein's anomaly - Severe aortic regurgitation - Pulmonary atresia - PAPVR or TAPVR, ONLY if there is lung hypoplasia or if documentation confirming the absence of lung hypoplasia does not exist. For subjects participating in the hemodynamic sub-study the following will also be considered exclusion criteria: - SVC stenosis >25% size of native vessel - PDA, AP window, TAPVR, PAPVR, or ASD sinus venosus with anomalous pulmonary veins - Down Syndrome - Subjects with deterioration of their clinical status within 3 months prior to Screening or during the Screening period. - Known moderate-to-severe restrictive (i.e., total lung capacity [TLC] < 60% of predicted value) or obstructive lung disease (i.e., forced expiratory volume in one second [FEV1] < 80 % of predicted value, and with FEV1 / forced vital capacity [FVC] < 70%) - Treatment with prostanoids within 1 month prior to Randomization - Subjects who initiated a PDE-5 inhibitor within 1 month prior to Randomization or those on a PDE-5 inhibitor for whom the dose has not been stable within 1 month prior to Randomization - Treatment with endothelin receptor antagonists (ERAs) within 1 month prior to Randomization - Subjects who initiated diuretics within 1 week prior to Randomization or subjects whose diuretic treatment has not been stable for at least 1 week prior to Randomization - Subjects being considered for an organ transplant

Additional Information

Official title A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Actelion.